Imanivec (Imatinib)

Imanivec (imatinib) is a tyrosine kinase inhibitor used in hematologic and solid‑tumor oncology.

• Chronic Myeloid Leukemia: achieves durable cytogenetic and molecular responses by inhibiting the BCR‑ABL kinase.
• Gastrointestinal Stromal Tumor: reduces tumor progression through inhibition of c‑KIT and PDGFR signaling.
• Philadelphia‑positive Acute Lymphoblastic Leukemia: provides targeted blockade of the abnormal BCR‑ABL fusion protein, supporting remission induction.

• Imatinib binds to the ATP‑binding pocket of BCR‑ABL, c‑KIT and PDGFR tyrosine kinases, stabilising them in an inactive conformation. This prevents phosphorylation of downstream substrates, halting proliferative and survival signaling pathways that drive malignant cell growth in affected cancers.

Imanivec may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects

• Nausea: mild to moderate upset stomach.
• Edema: swelling of the extremities, especially ankles.
• Fatigue: generalized tiredness.
• Diarrhea: loose stools occurring intermittently.

Serious or Rare Side Effects

• Hepatotoxicity: elevated liver enzymes or liver injury.
• Cardiotoxicity: reduced left‑ventricular ejection fraction.
• Severe neutropenia: marked decrease in white blood cells increasing infection risk.

Before initiating therapy, clinicians should assess baseline organ function and monitor patients regularly.

• Baseline labs: obtain complete blood count, liver and renal function tests.
• Cardiac monitoring: evaluate ejection fraction in patients with pre‑existing heart disease.
• Drug interactions: review concomitant medications for CYP3A4 modulators.
• Pregnancy and lactation: avoid use unless benefits outweigh potential risks.
• Store at ambient temperature: keep below 25 °C in the original container, protect from moisture and direct sunlight.

Imatinib interacts with several drug classes that can alter its exposure or increase toxicity.

Major Interactions (Avoid)

• Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may markedly reduce imatinib plasma levels.
• Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): can increase imatinib exposure and risk of adverse events.

Moderate Interactions (Monitor Closely)

• Acid‑reducing agents (e.g., proton pump inhibitors, antacids): may modestly lower absorption.
• Anticoagulants (e.g., warfarin): may enhance anticoagulant effect, requiring INR monitoring.
• Vaccines: live attenuated vaccines should be avoided during treatment.